Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Pharmacyclics, Inc. (PCYC - Analyst Report) announced recently that data from a phase II study (n=111) on its cancer candidate ibrutinib was published in the New England Journal of Medicine (NEJM). The study is evaluating the safety and efficacy of the candidate (as a monotherapy) in patients suffering from relapsed/refractory mantle cell lymphoma (MCL). Pharmacyclics stated in its press release that MCL, a form of B-cell non-Hodgkin lymphoma, generally affects older adults.

The MCL patients enrolled in the open-label, multicenter study were treated with 560mg of ibrutinib (once daily). They were divided into two groups. While one group of patients were previously treated with Takeda Pharmaceutical Company Limited’s Velcade (bortezomib), the other group included those who had not undergone any such prior therapy.

Data from the study revealed an overall response rate (the primary endpoint of the study) of 68% across both groups. While the median overall survival for the study is yet to be reached, the median progression free survival was found to be 13.9 months. The candidate was also found to be well tolerated in the study. Moreover, data from another study on ibrutinib as a monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma was also published in the NEJM.

Pharmacyclics is co-developing ibrutinib with Janssen Biotech, Inc., a Johnson & Johnson (JNJ - Analyst Report) company. We expect investor focus to remain on the development of ibrutinib.

Pharmacyclics, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Celgene Corporation (CELG - Analyst Report) appears to be more attractive in the biopharma space with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%